U.S. Insights: Trends in At-Risk Generic Drug Launches (2017 - 2024)

In this report, we analyzed 27 brand drugs that faced a first-time at-risk generic drug launch from January 2017 through June 2024.

Key findings include:

- $25.7B in peak gross sales across these brand drugs, with Copaxone ($5.1B) and Tecfidera ($3.9B) leading in peak sales.

- 51 at-risk launches from 29 different generic manufacturers

- Potential at-risk launches: 7 upcoming opportunities represented by brand drugs totaling $13.6B in peak sales, with MSN leading the pipeline.

Stay informed on the evolving landscape of at-risk launches and potential opportunities in the generic market by reading the full report.